OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Ji Yuan Wu, Feng Meng, Henry Y. Lu, et al.
Blood (2008) Vol. 111, Iss. 7, pp. 3821-3829
Open Access | Times Cited: 112
Ji Yuan Wu, Feng Meng, Henry Y. Lu, et al.
Blood (2008) Vol. 111, Iss. 7, pp. 3821-3829
Open Access | Times Cited: 112
Showing 1-25 of 112 citing articles:
Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jorge E. Cortés
Cancer Control (2009) Vol. 16, Iss. 2, pp. 122-131
Open Access | Times Cited: 243
Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jorge E. Cortés
Cancer Control (2009) Vol. 16, Iss. 2, pp. 122-131
Open Access | Times Cited: 243
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
François‐Xavier Mahon, Sandrine Hayette, Valérie Lagarde, et al.
Cancer Research (2008) Vol. 68, Iss. 23, pp. 9809-9816
Open Access | Times Cited: 210
François‐Xavier Mahon, Sandrine Hayette, Valérie Lagarde, et al.
Cancer Research (2008) Vol. 68, Iss. 23, pp. 9809-9816
Open Access | Times Cited: 210
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
Dale Bixby, Moshe Talpaz
Hematology (2009) Vol. 2009, Iss. 1, pp. 461-476
Open Access | Times Cited: 194
Dale Bixby, Moshe Talpaz
Hematology (2009) Vol. 2009, Iss. 1, pp. 461-476
Open Access | Times Cited: 194
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart, et al.
Blood (2011) Vol. 117, Iss. 12, pp. 3409-3420
Open Access | Times Cited: 187
Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart, et al.
Blood (2011) Vol. 117, Iss. 12, pp. 3409-3420
Open Access | Times Cited: 187
Function, regulation and pathological roles of the Gab/DOS docking proteins
Franziska U. Wöhrle, Roger J. Daly, Tilman Brummer
Cell Communication and Signaling (2009) Vol. 7, Iss. 1
Open Access | Times Cited: 173
Franziska U. Wöhrle, Roger J. Daly, Tilman Brummer
Cell Communication and Signaling (2009) Vol. 7, Iss. 1
Open Access | Times Cited: 173
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Ami B. Patel, Thomas O’Hare, Michael W. Deininger
Hematology/Oncology Clinics of North America (2017) Vol. 31, Iss. 4, pp. 589-612
Open Access | Times Cited: 167
Ami B. Patel, Thomas O’Hare, Michael W. Deininger
Hematology/Oncology Clinics of North America (2017) Vol. 31, Iss. 4, pp. 589-612
Open Access | Times Cited: 167
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
Dale Bixby, Moshe Talpaz
Leukemia (2010) Vol. 25, Iss. 1, pp. 7-22
Closed Access | Times Cited: 161
Dale Bixby, Moshe Talpaz
Leukemia (2010) Vol. 25, Iss. 1, pp. 7-22
Closed Access | Times Cited: 161
Functions of the Lyn tyrosine kinase in health and disease
Evan Ingley
Cell Communication and Signaling (2012) Vol. 10, Iss. 1, pp. 21-21
Open Access | Times Cited: 161
Evan Ingley
Cell Communication and Signaling (2012) Vol. 10, Iss. 1, pp. 21-21
Open Access | Times Cited: 161
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant, Nina Fenouille, Gabriela Alexe, et al.
Cancer Cell (2014) Vol. 25, Iss. 2, pp. 226-242
Open Access | Times Cited: 138
Alexandre Puissant, Nina Fenouille, Gabriela Alexe, et al.
Cancer Cell (2014) Vol. 25, Iss. 2, pp. 226-242
Open Access | Times Cited: 138
Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Kathrin M. Bernt, Stephen P. Hunger
Frontiers in Oncology (2014) Vol. 4
Open Access | Times Cited: 137
Kathrin M. Bernt, Stephen P. Hunger
Frontiers in Oncology (2014) Vol. 4
Open Access | Times Cited: 137
Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
Ursula Bommhardt, Burkhart Schraven, Luca Simeoni
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3500-3500
Open Access | Times Cited: 132
Ursula Bommhardt, Burkhart Schraven, Luca Simeoni
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3500-3500
Open Access | Times Cited: 132
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Luana Bavaro, Maurizio Martelli, Michèle Cavo, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6141-6141
Open Access | Times Cited: 79
Luana Bavaro, Maurizio Martelli, Michèle Cavo, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6141-6141
Open Access | Times Cited: 79
Multiple roles of Lyn kinase in myeloid cell signaling and function
Patrizia Scapini, Shalini Pereira, Hong Zhang, et al.
Immunological Reviews (2009) Vol. 228, Iss. 1, pp. 23-40
Open Access | Times Cited: 130
Patrizia Scapini, Shalini Pereira, Hong Zhang, et al.
Immunological Reviews (2009) Vol. 228, Iss. 1, pp. 23-40
Open Access | Times Cited: 130
Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
Abhishek Samanta, Sharmistha Chakraborty, Yingjun Wang, et al.
Oncogene (2009) Vol. 28, Iss. 14, pp. 1669-1681
Open Access | Times Cited: 114
Abhishek Samanta, Sharmistha Chakraborty, Yingjun Wang, et al.
Oncogene (2009) Vol. 28, Iss. 14, pp. 1669-1681
Open Access | Times Cited: 114
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
Wenyong W. Zhang, Jorge E. Cortés, Hui Yao, et al.
Journal of Clinical Oncology (2009) Vol. 27, Iss. 22, pp. 3642-3649
Open Access | Times Cited: 110
Wenyong W. Zhang, Jorge E. Cortés, Hui Yao, et al.
Journal of Clinical Oncology (2009) Vol. 27, Iss. 22, pp. 3642-3649
Open Access | Times Cited: 110
Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
Elias Jabbour, Jorge E. Cortés, Hagop M. Kantarjian
Clinical Lymphoma Myeloma & Leukemia (2013) Vol. 13, Iss. 5, pp. 515-529
Open Access | Times Cited: 101
Elias Jabbour, Jorge E. Cortés, Hagop M. Kantarjian
Clinical Lymphoma Myeloma & Leukemia (2013) Vol. 13, Iss. 5, pp. 515-529
Open Access | Times Cited: 101
Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells
Romain Gioia, Cédric Leroy, Claire Drullion, et al.
Blood (2011) Vol. 118, Iss. 8, pp. 2211-2221
Open Access | Times Cited: 100
Romain Gioia, Cédric Leroy, Claire Drullion, et al.
Blood (2011) Vol. 118, Iss. 8, pp. 2211-2221
Open Access | Times Cited: 100
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
Wolfgang Warsch, Christoph Walz, Veronika Sexl
Blood (2013) Vol. 122, Iss. 13, pp. 2167-2175
Open Access | Times Cited: 99
Wolfgang Warsch, Christoph Walz, Veronika Sexl
Blood (2013) Vol. 122, Iss. 13, pp. 2167-2175
Open Access | Times Cited: 99
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Helmut König, Mhairi Copland, Su Chu, et al.
Cancer Research (2008) Vol. 68, Iss. 23, pp. 9624-9633
Open Access | Times Cited: 97
Helmut König, Mhairi Copland, Su Chu, et al.
Cancer Research (2008) Vol. 68, Iss. 23, pp. 9624-9633
Open Access | Times Cited: 97
GAB2—a Scaffolding Protein in Cancer
Sarah J. Adams, Iraz T. Aydin, Jülide Tok Çelebi
Molecular Cancer Research (2012) Vol. 10, Iss. 10, pp. 1265-1270
Open Access | Times Cited: 86
Sarah J. Adams, Iraz T. Aydin, Jülide Tok Çelebi
Molecular Cancer Research (2012) Vol. 10, Iss. 10, pp. 1265-1270
Open Access | Times Cited: 86
Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
Min Chen, Paolo Gallipoli, Donna DeGeer, et al.
JNCI Journal of the National Cancer Institute (2013) Vol. 105, Iss. 6, pp. 405-423
Open Access | Times Cited: 74
Min Chen, Paolo Gallipoli, Donna DeGeer, et al.
JNCI Journal of the National Cancer Institute (2013) Vol. 105, Iss. 6, pp. 405-423
Open Access | Times Cited: 74
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
Jessica T. Leonard, Joelle Rowley, Christopher A. Eide, et al.
Science Translational Medicine (2016) Vol. 8, Iss. 354
Open Access | Times Cited: 72
Jessica T. Leonard, Joelle Rowley, Christopher A. Eide, et al.
Science Translational Medicine (2016) Vol. 8, Iss. 354
Open Access | Times Cited: 72
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
Laura N. Eadie, P Dang, V. A. Saunders, et al.
Leukemia (2016) Vol. 31, Iss. 1, pp. 75-82
Closed Access | Times Cited: 63
Laura N. Eadie, P Dang, V. A. Saunders, et al.
Leukemia (2016) Vol. 31, Iss. 1, pp. 75-82
Closed Access | Times Cited: 63
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells
Haojian Zhang, Cong Peng, Yiguo Hu, et al.
Nature Genetics (2012) Vol. 44, Iss. 8, pp. 861-871
Open Access | Times Cited: 71
Haojian Zhang, Cong Peng, Yiguo Hu, et al.
Nature Genetics (2012) Vol. 44, Iss. 8, pp. 861-871
Open Access | Times Cited: 71
Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner
Teodora Pene-Dumitrescu, Thomas E. Smithgall
Journal of Biological Chemistry (2010) Vol. 285, Iss. 28, pp. 21446-21457
Open Access | Times Cited: 70
Teodora Pene-Dumitrescu, Thomas E. Smithgall
Journal of Biological Chemistry (2010) Vol. 285, Iss. 28, pp. 21446-21457
Open Access | Times Cited: 70
